Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 43Neoplasms 13Neoplasm Metastasis 8Sarcoma 7Carcinoma, Non-Small-Cell Lung 5Triple Negative Breast Neoplasms 4Sarcoma, Ewing 2Rhabdomyosarcoma 2Prostatic Neoplasms 2Liposarcoma 2Leiomyosarcoma 2Inflammatory Breast Neoplasms 2Carcinoma 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasm, Residual 1Metastatic Urothelial Cell Cancer 1Lymphoma 1Lung Neoplasms 1Ketosis 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Hemangioendothelioma, Epithelioid 1

Interventions

Ifosfamide 11Methotrexate 9Doxorubicin 7Magnetic Resonance Spectroscopy 6Filgrastim 6Cisplatin 6Leucovorin 5Etoposide 5X-Rays 4Specimen Handling 4Sirolimus 4Phantoms, Imaging 4Gemcitabine 4temsirolimus 3sargramostim 3dinutuximab 3cixutumumab 3Radiotherapy 3Nuclear Medicine Department, Hospital 3Granulocyte-Macrophage Colony-Stimulating Factor 3Dexrazoxane 3Cyclophosphamide 3Biopsy 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2samarium Sm-153 lexidronam 2palbociclib 2olaparib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Osteosarcoma × eribulin × Clear all
NCT02097238 2020-05-19

Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma

National Cancer Institute (NCI)

Phase 2 Completed
19 enrolled 12 charts
Sarcoma

Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡